Autopsy report · NCT03059511

Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“We conclude that the doses we administered were safe, but too low. We plan to continue the study with higher doses (0.1 mg/kg iv and 0.2 mg/kg intranasal).”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 10 months before it stopped.
51 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: University Children's Hospital, Zurich
Sponsor type: University, hospital or other
Conditions: Pharmacokinetic
Interventions: Nalbuphine
Participants: 51
Sites: 1
Countries: Switzerland

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.